Physician profile
John Samaan
NPI 1225325988
$1,199.60
in general payments reported to CMS, 2019-2025
13 companies · $571 in 2025
The $571 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $169 · 2020: $265 · 2021: $176 · 2022: $17.63 · 2025: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $571.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $315.19 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $261.26 | 2019-2025 | Spravato |
| Neurocrine Biosciences, INC. | $227.74 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $107.45 | 2019-2025 | Rexulti |
| Indivior INC. | $68.75 | 2025 | Sublocade |
| Vanda Pharmaceuticals INC. | $38.57 | 2020 | |
| Almatica Pharma LLC | $38.14 | 2025 | Loreev Xr |
| Allergan, INC. | $34.27 | 2020 | |
| Lundbeck LLC | $28.10 | 2025 | Rexulti |
| Alkermes, INC. | $23.96 | 2019 | |
| Brainsway USA INC | $23.41 | 2025 | Deep Tms System |
| Orexo US, INC. | $17.63 | 2022 | |
| Lilly USA, LLC | $15.13 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Samaan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.